Catherine Skari

A milestone in the treatment of b-thalassaemia – The 1st gene therapy for Transfusion Dependent β-Thalassaemia wins approval in Europe

  Zynteglo, Bluebird Bio’s ex vivo gene therapy for β-thalassaemia, got a green light from the EMA for conditional marketing…

Read More »

TIF actively participates in the 72nd World Health Assembly Meetings in Geneva, Switzerland

Read More »

World Blood Donor Day – 14 June 2019

This year, World Blood Donor Day will once again be celebrated around the world on 14 June! The event serves…

Read More »

TIF to organize a Capacity Building Workshop for Patients’ Organizations and individuals with thalassaemia in October 2019!

  This fall TIF is coming to Germany✈️✈️ and is more than excited to announce its forthcoming Capacity Building Workshop…

Read More »

TIF’s e-registry for patients with thalassaemia is ready for piloting

  TIF with support from Celgene Corporation, has developed a disease specific e-registry with health record for patients with thalassaemia.…

Read More »

Bone Marrow Transplantation in β-Thalassaemia (2018)

An educational leaflet with important information for β-thalassaemia patients on hematopoietic stem cell transplantation (HSCT), also known as bone marrow…

Read More »

FDA Grants Priority Review to Luspatercept-aamt for Anemia in Adults With NTD β-Thalassaemia

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2022. In addition, the…

Read More »

Delegation Visit to Austria – 11-13 April 2019

TIF’s Board of Directors Member and Expert Patient, Mr. George Constantinou, and TIF’s collaborators Dr. Eva-Maria Knoll and Dr. Anne…

Read More »

Living with Transfusion-Dependent β-Thalassaemia (TDT)

In its most severe form and without adequate care, thalassaemia can be lethal in early childhood, and although  International Thalassaemia…

Read More »

Delegation Visit to Vietnam – 24 & 25 April 2019

Read More »